.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

The Era of Targeted Therapy for Acute Myeloid Leukemia

EP. 1: Acute Myeloid Leukemia: Understanding Biologic Drivers

January 19th 2018

EP. 2: The Microenvironment and Epigenetics in AML

January 19th 2018

EP. 3: Recommended Molecular Testing in Acute Myeloid Leukemia

January 19th 2018

EP. 4: Debating an Algorithm for Molecular Testing in AML

January 19th 2018

EP. 5: Promise of Recently Approved Agents for AML: CPX-351

January 19th 2018

EP. 6: Considerations for CPX-351 in Acute Myeloid Leukemia

January 19th 2018

EP. 7: RATIFY Trial: Midostaurin's Role in Treating AML

January 19th 2018

EP. 8: Considering Midostaurin for Acute Myeloid Leukemia

January 19th 2018

EP. 9: Enasidenib's Role in IDH-Mutant Acute Myeloid Leukemia

January 19th 2018

EP. 10: AML: Identifying Practical Concerns With Enasidenib

January 19th 2018

EP. 11: Treating CD33-Positive AML With Gemtuzumab Ozogamicin

January 19th 2018

EP. 12: MRD's Potential Role in Treating Acute Myeloid Leukemia

January 19th 2018

EP. 13: Second-Generation FLT3 Inhibitors in AML: Quizartinib

January 19th 2018

EP. 14: Emerging FLT3 Inhibitors in AML

January 19th 2018

EP. 15: Defining the Challenges of FLT3 Inhibition in AML

January 19th 2018

EP. 16: Promising Targeted Approaches in AML

January 19th 2018

EP. 17: Promising Immunotherapy Approaches in AML

January 19th 2018